LONDON (Alliance News) - Integumen PLC on Friday said it has launched the Labskin human clone skin testing platform into the medical device and clinical research sectors.
Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment.
The personal healthcare company said when combined with human volunteers, Labskin AI platform creates double the number of skin tests possible that are more reliable and accurate than human volunteers alone.
As a result, the test process requires 50% less human volunteers for each trial, reducing recruitment time and cutting costs. The platform also lowers error rate by reducing number of human volunteers who are not sticking to test regime.
Labskin can double the output of test results requiring fewer test volunteers and lower project management time, delivering faster, more reliable and consistent results for their skin care, health care, wound care and pharmaceutical clients, all at a lower cost to our partners," explained Integumen Chief Executive Gerard Brandon.
Integumen shares were trading 18% higher on Friday at 1.92 pence each.
